Flexion Therapeutics Stock News

BURLINGTON, Mass., Nov. 06, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 3,315 restricted stock units.

BURLINGTON, Mass., Nov. 05, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -2.04% and 0.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock

BURLINGTON, Mass., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today reported financial results and recent business highlights for the quarter ended September 30, 2020.

Miller Value Partners recently released its Q3 2020 Investor Letter, a copy of which you can download here. The Opportunity Equity Fund posted a return of 13.01% for the quarter (net of fees), outperf

BURLINGTON, Mass., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that it will report its third-quarter 2020 financial results after the close of the U.S. f

BURLINGTON, Mass., Aug. 19, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced the appointment of Elizabeth (Liz) Kwo, MD, Staff Vice President, Clinical Data Analytics

BURLINGTON, Mass., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced equity inducement grants to two new employees consisting of 25,315 restricted stock units.

This article will reflect on the compensation paid to Mike Clayman who has served as CEO of Flexion Therapeutics, Inc...

The

Shares of Flexion Therapeutics (NASDAQ: FLXN) saw some unusual options activity on Thursday. Following the unusual option alert, the stock price moved down to $12.23. * Sentiment: BULLISH * Option T

Flexion Therapeutics (FLXN) delivered earnings and revenue surprises of -8.57% and -0.07%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

* Company reported ZILRETTA® (triamcinolone acetonide extended-release injectable suspension) net sales of $15.5 million in second quarter 2020 * Flexion resumed enrollment in Phase 1 dose-esc

ValuEngine downgraded shares of Flexion Therapeutics (NASDAQ:FLXN) from a buy rating to a hold rating in a research note released on Wednesday, ValuEngine reports. FLXN has been the topic of several o